Over the past few years, Mucos CZ has successfully distributed Wobenzym products primarily in Russia, Czech Republic and Slovakia. This controlling interest in Mucos CZ reflects the strategic importance of Central and Eastern European markets to Atrium in reference to Wobenzym’s potential and the potential for future cross-selling opportunities particularly in Russia.
The transaction includes an obligation on or before 31 December 2015 to acquire the remaining 30% of Mucos CZ shares allowing for a proper transition.
The acquisition price of this transaction is established on a multiple of 4.75 times the last 12 months EBITDA. This transaction of US$15.9m will be financed with existing credit facilities.
Source: Atrium Innovations
© FoodBev Media Ltd 2024